Information updates

Updated ASCIA Action Plans for Anaphylaxis and Allergic Reactions

Aug 10, 2016
ASCIA has released updated Action Plans for Anaphylaxis and Allergic Reactions on its website:
www.allergy.org.au/health-professionals/anaphylaxis-resources/ascia-action-plan-for-anaphylaxis

The main changes are an increased emphasis of key messages, inclusion of images to show how to position a person with anaphylaxis and revised wording regarding the importance of giving the adrenaline (epinephrine) autoinjector first, then asthma medication in a person with severe allergy and asthma.

All ASCIA anaphylaxis resources and e-training courses have been updated with the changes that have been made to the ASCIA action plans.

Instructions for the EpiPen® adrenaline autoinjector remain unchanged in Australia and New Zealand. However, ASCIA has added "Hold leg still" to the instructions.

If you have any questions regarding EpiPen® instructions please email the Alphapharm-Mylan Medical Affairs team on This email address is being protected from spambots. You need JavaScript enabled to view it. or phone 1800 274 276.

Patient outcomes can be improved by ensuring that acute management of anaphylaxis is consistent with ASCIA Action Plans. In an anaphylaxis emergency, ASCIA Action Plans provide guidance on how and when to give the adrenaline autoinjector.
It is therefore essential that all patients prescribed an adrenaline autoinjector are provided with an ASCIA Action Plan for Anaphylaxis.

ASCIA Action Plans should be reviewed when patients are reassessed by their doctor, and each time they obtain a new adrenaline autoinjector prescription, which is approximately every 12 to 18 months.

Content updated 10 August 2016